StockData
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY) stock

HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.01+0.05 (+0.15%)

Close on Nov 17, 2026Market cap $1.92BP/E 10.7Yield –

Harmony Biosciences operating margin

Operating margin is operating income as a percentage of revenue.

Harmony Biosciences's operating margin for the twelve months ending Jun 30, 2026 was 24.0%. For fiscal 2025 it was 24.0%, against 26.7% the year before. The highest annual figure on record is 33.0% in fiscal 2023.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202524.0%−2.7
FY2024Dec 31, 202426.7%−6.3
FY2023Dec 31, 202333.0%+5.5
FY2022Dec 31, 202227.4%−1.2
FY2021Dec 31, 202128.7%+18.0
FY2020Dec 31, 202010.6%+2444.4
FY2019Dec 31, 2019-2433.8%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202634.2%+10.2
Q1 FY2026Mar 31, 202617.3%−13.1
Q4 FY2025Dec 31, 202515.8%−11.9
Q3 FY2025Sep 30, 202527.3%−5.8
Q2 FY2025Jun 30, 202524.0%+11.7
Q1 FY2025Mar 31, 202530.4%−3.2
Q4 FY2024Dec 31, 202427.7%+3.8
Q3 FY2024Sep 30, 202433.2%−7.1
Q2 FY2024Jun 30, 202412.4%−22.6
Q1 FY2024Mar 31, 202433.7%−0.3
Q4 FY2023Dec 31, 202323.9%−13.2
Q3 FY2023Sep 30, 202340.3%+30.1
Q2 FY2023Jun 30, 202334.9%+4.0
Q1 FY2023Mar 31, 202333.9%+1.6
Q4 FY2022Dec 31, 202237.1%+5.7
Q3 FY2022Sep 30, 202210.2%−15.9
Q2 FY2022Jun 30, 202230.9%−0.6
Q1 FY2022Mar 31, 202232.3%+7.9
Q4 FY2021Dec 31, 202131.4%+17.6
Q3 FY2021Sep 30, 202126.1%+3.3
Q2 FY2021Jun 30, 202131.6%+12.3
Q1 FY2021Mar 31, 202124.4%+72.8
Q4 FY2020Dec 31, 202013.8%–
Q3 FY2020Sep 30, 202022.8%–
Q2 FY2020Jun 30, 202019.2%–
Q1 FY2020Mar 31, 2020-48.4%–

More Harmony Biosciences figures

See a number that looks wrong?